Ownership history in SummitTX Capital, L.P. Β· 3 quarters on record
This page tracks every 13F SEC filing in which SummitTX Capital, L.P. reported a position in VERA THERAPEUTICS INC (VERA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π SummitTX Capital, L.P. outperformed the S&P 500 by +5.1% annually on this VERA position. Average cost basis: $24.02. Maximum drawdown during holding period: β1.9%.
π₯ Exceptional β beat the S&P 500 by 5.1% per year on this position.
2 quarters analyzed
Best entry: $24.02 (2025 Q1) Β· Worst: $24.02 (2025 Q1)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
1 add Β· 1 trim. Bought during 0 of 1 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.11% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size